PreludeDx to Present New Data on the Clinical Utility of DCISionRT in Australian Patients with DCIS at the 2023 San Antonio Breast Cancer Symposium In data presented at SABCS23, DCISionRT changed radiation therapy decisions in 41% of DCIS patients

PreludeDx™ to Present Multiple Presentations at the 2023 San Antonio Breast Cancer Symposium PreludeDx today announced that data will be presented in two separate poster presentations at the 2023 San Antonio Breast Cancer Symposium (SABCS).

PredictHQ Introduces Notifications Platform for Instant Alerts on Incoming Demand Impact SAN FRANCISCO, July 28, 2020 (GLOBE NEWSWIRE) -- PredictHQ, the demand intelligence company, today announced a new Notifications platform that makes its API of intelligent event data instantly...

PredictHQ Announces $22M in Funding to Advance Demand Intelligence SAN FRANCISCO, Feb. 12, 2020 (GLOBE NEWSWIRE) -- PredictHQ, the demand intelligence company, today announced $22 million in Series B funding led by Sutter Hill Ventures and joined by existing...